Tarsus Pharmaceuticals, Inc. TARS
We are a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. 10-K, Item 1
- Headquarters
- Irvine, CA
- CEO
- Bobak R. Azamian
- Next results
- around Feb 22, 2027
TARS among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
25 new risk paragraphs. 10-K filed Feb 23, 2026 against Feb 25, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
0facts worth reading about all 11 checks found nothing to note
-
Receivables +81.9% ($46.8M to $85.1M) vs revenue +146.7% ($183.0M to $451.4M), -64.8 pts apart
-
Cash from operations −$12.5M vs net income −$66.4M (FY ending Dec 31, 2025)
-
Inventory +66.9% ($2.6M to $4.4M) vs revenue +146.7% ($183.0M to $451.4M), -79.8 pts apart
8 more checks with nothing to note
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Accrued Commercial and Government Rebates Impacted by Estimated Payer Mix
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
25 paragraphs in Risk Factors that were not in the 10-K filed Feb 25, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
Our future financial performance and our ability to develop, manufacture and commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
Additionally, the U.S. government has made statements and taken certain actions including the imposition of tariffs, that have led to changes in U.S. and international trade policies towards China and other countries. It remains unclear what additional actions, if any, will be taken by the U.S. or other governments with respect to…
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
We received approval by the FDA for XDEMVY for the treatment of Demodex blepharitis in the U.S. and began generating revenue from product sales during the third quarter of 2023. Our ability to become and remain profitable is heavily
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
A further example of comprehensive and evolving regulatory requirements is data privacy regulations surrounding personal data and protected health information including the EU’s General Data Protection Regulation, or GDPR, which imposes strict requirements on controllers and processors of personal data, including special protections for…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $25.8M | $17.4M | $183.0M | $451.4M |
| Net income | −$62.1M | −$135.9M | −$115.6M | −$66.4M |
| Operating cash flow | −$49.0M | −$117.5M | −$83.0M | −$12.5M |
| Free cash flow | −$49.5M | −$119.0M | −$84.6M | −$22.3M |
Revenue, FY2020 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$451.4M ▲ 146.7% in FY2025−$66.4M in FY2025−$22.3M in FY2025
Recent filings
4 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 13, 2026Bobak Azamian (Officer) gave notice of a planned sale of 10,000 shares worth about $802K Form 144, approximate sale date Nov 13, 2026, under a 10b5-1 plan adopted Dec 9, 2025
-
Planned saleNov 3, 2026Andrew Goldberg (Board of Directors) adopted a 10b5-1 trading plan reported in the 10-Q, up to 20,000 shares, runs to Sep 10, 2027
-
8-KNov 3, 2026Quarterly results 8-K item 2.02
-
10-QNov 3, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
Tarsus Pharmaceuticals, Inc., Irvine, CA · from the 10-K filed Feb 23, 2026
We are a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. We launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, for the treatment of Demodex blepharitis, in August 2023 after receiving U.S. Food and Drug Administration (“FDA”) approval in July 2023. Demodex blepharitis is caused by the infestation of Demodex mites.
- Headquarters
- Irvine, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 3, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 23, 2026 (open at SEC), compared with the 10-K filed Feb 25, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TARS/export.csv") into a cell.